June 2026 Research Update

This month added a clearer picture of how often chronic nonbacterial osteomyelitis (CNO) and inflammatory bowel disease (IBD) show up together in children, and what the course can look like over time. In a French national cohort, this combination was uncommon, but most children were reported to be in remission at their last follow-up. The same report also showed that even when remission is reached, relapse can still occur, which helps explain why the course can feel unpredictable for some families. [1]

In the cohort of 37 children, Crohn's disease was more common than ulcerative colitis among those who also had CNO. Bone involvement most often affected the lower limbs and pelvis, and skin problems were reported in more than a third of patients. The timing varied: CNO could appear before IBD, after IBD, or around the same time, sometimes separated by about a year. [1]

Treatment patterns in the cohort frequently included anti-TNF-alpha medicines (drugs that lower a major inflammation signal), sometimes used alone. Remission was reported in many patients receiving anti-TNF therapy, but relapse was also reported in a notable portion, showing that improvement may not always be permanent. Because this was a description of routine care rather than a head-to-head trial, it cannot prove which treatment caused remission, but it does show what was commonly used in this group. [1]

A separate single-patient report also noted ulcerative colitis occurring together with chronic nonbacterial osteomyelitis. In this 14-year-old boy, infliximab treatment was followed by improvement in diarrhea and joint pain, normalization of inflammatory markers, and marked improvement of the bone lesions on follow-up MRI. A single report cannot tell how common the overlap is, but it adds to the wider pattern that gut inflammation and bone inflammation can coexist. [2]

For families dealing with IBD and ongoing bone pain, these studies help clarify that CNO can be part of the picture, even though it appears to be rare among children with IBD. The cohort report suggests that many children can reach a period of remission over a few years, but it also makes clear that relapse is not unusual, so the course can include ups and downs. This information may matter now for understanding what symptoms and timelines have been reported in similar patients, while treatment comparisons remain uncertain because the data describe routine care rather than proving one best approach. [1]

These reports also add practical context about what problems may travel together, such as skin symptoms along with bone and gut inflammation, and that CNO may start before, after, or near the time IBD is diagnosed. What remains unclear from this month is how to predict which child will relapse, or which specific medicine works best for both conditions at the same time. [1]

This month emphasized how widely CNO or CRMO can vary from one child to another, including presentations that do not start with clear bone pain. Across a case report and a small case series, fever of unknown origin appeared as an early or dominant feature in some patients, and pain could involve less typical areas such as the neck. These reports also showed that some patients improved with anti-inflammatory medicines alone, while others needed additional immune-modifying medicines to get symptoms under control. [3] [4]

In one 12-year-old girl investigated for persistent fever, imaging showed multiple bone areas with inflammation-like changes, and a bone biopsy helped rule out infection and cancer. Her symptoms improved after a stepwise approach that included naproxen, then methotrexate and prednisone. This case adds to the idea that, for some patients, CNO can sit behind a long workup for fever before the diagnosis becomes clear. [3]

In a four-patient pediatric series, all children started with NSAIDs, but one needed escalation to methotrexate and adalimumab (an anti-TNF medicine). In three of the cases, blood testing before treatment found higher levels of several immune signals, including IL-6, IL-10, and IL-33, showing that both pro- and anti-inflammatory signals may be elevated at the same time in some children. Because the series was very small, it is not clear how often these cytokine patterns occur in CNO more broadly. [4]

Another case report described CRMO occurring as part of a broader, genetically confirmed condition called trichohepatoenteric syndrome, with symptoms flaring after an intestinal infection. The report described multiple body systems being involved, including gut disease that looked similar to IBD and a spinal cord cavity (syringomyelia), alongside CRMO. As a single case, it mainly highlights that bone inflammation can be one piece of a more complex immune-related illness in rare situations. [5]

For patients and caregivers, these reports help explain why getting to a CNO diagnosis can sometimes take time, especially when fever is the main symptom or when pain shows up in unusual places like the neck. They also show that some children improve with initial anti-inflammatory treatment, while others may need added medicines, which reflects real-world variability rather than a single typical path. The evidence here is early and based on a small number of patients, so it is most useful for understanding what is possible, not for predicting what will happen to any one child. [3] [4]

The small cytokine findings (higher IL-6, IL-10, and IL-33 before treatment in a few children) are mainly research context right now. They help clarify that blood immune signals may sometimes be elevated in CNO, but it is still unknown whether these tests can reliably support diagnosis, track disease activity, or guide treatment choices. [4]

This month brought a focused, early look at one possible inherited pathway that could drive CNO in some families, especially affecting the jawbone. A study in a single Chinese family linked a specific SLC2A10 gene variant with mandibular chronic nonbacterial osteomyelitis and then tested how it might cause damage. The overall picture was that the variant appeared to push immune cells into a higher-sugar-use state, which went along with stronger inflammation signals and more activity of bone-eating cells. [6]

In laboratory experiments, the variant increased glucose uptake and markers of glycolysis (a way cells make energy from sugar) in macrophages, alongside higher levels of inflammatory signals such as TNF-alpha, IL-1beta, and IL-6. It also sped up osteoclast development (cells that break down bone) and reduced signs of osteogenesis (bone-building activity). This helps connect immune activation and bone breakdown in a concrete, testable way, at least for this family and this gene change. [6]

In zebrafish experiments, the same variant increased inflammation-related markers, increased oxidative stress, and reduced bone mineralization. A laboratory inhibitor of glycolysis partially reversed abnormal cell behaviors in vitro, suggesting that the cell energy pathway was part of the effect. Because this work is mainly lab and animal research from one family, it does not show that the same mechanism explains most CRMO cases, but it does provide a specific lead for future studies. [6]

For patients, this study mainly adds understanding rather than changing care right now. It helps clarify one way CNO could happen in a small subset of families: a genetic change that makes immune cells more inflammatory and boosts bone breakdown. What remains uncertain is how often this gene is involved in CRMO more broadly, and whether targeting cell energy use would be helpful or safe in people with CNO. [6]

This research may matter more in the future if other studies find similar changes in more patients, or if it leads to better ways to classify different forms of CNO (for example, jaw-predominant disease). For now, its main value is explaining a possible biological chain from gene to immune activation to bone damage, using lab and animal results as supportive evidence. [6]